PHStrader

I have been researching melanoma drugs for the last six months and based on what I have found PV-10 looks to be one of the more promissing investigational new melanoma drugs currently being tested in FDA / TGA trials right now. Based on the published Phase 2 results it looks like PV-10 works as well or better than any of the other new melanoma drugs. Objective and Complete response results are better than the other new melanoma drugs and from what I have read the side effects are minimal to moderate. Provectus Pharmaceuticals currently has over 40 patients enrolled in the PV-10 compassionate use program and is in discussion with the FDA designing their Phase 3 trial. I would definately look into PV-10 as an option.  http://www.pvct.com

Dennis

I have been researching melanoma drugs for the last six months and based on what I have found PV-10 looks to be one of the more promissing investigational new melanoma drugs currently being tested in FDA / TGA trials right now. Based on the published Phase 2 results it looks like PV-10 works as well or better than any of the other new melanoma drugs. Objective and Complete response results are better than the other new melanoma drugs and from what I have read the side effects are minimal to moderate. Provectus Pharmaceuticals currently has over 40 patients enrolled in the PV-10 compassionate use program and is in discussion with the FDA designing their Phase 3 trial. I would definately look into PV-10 as an option.  http://www.pvct.com

Dennis

I have been researching melanoma drugs for the last six months and based on what I have found PV-10 looks to be one of the more promissing investigational new melanoma drugs currently being tested in FDA / TGA trials right now. Based on the published Phase 2 results it looks like PV-10 works as well or better than any of the other new melanoma drugs. Objective and Complete response results are better than the other new melanoma drugs and from what I have read the side effects are minimal to moderate. Provectus Pharmaceuticals currently has over 40 patients enrolled in the PV-10 compassionate use program and is in discussion with the FDA designing their Phase 3 trial. I would definately look into PV-10 as an option.  http://www.pvct.com

Dennis

I have been researching melanoma drugs for the last six months and based on what I have found PV-10 looks to be one of the more promissing investigational new melanoma drugs currently being tested in FDA / TGA trials right now. Based on the published Phase 2 results it looks like PV-10 works as well or better than any of the other new melanoma drugs. Objective and Complete response results are better than the other new melanoma drugs and from what I have read the side effects are minimal to moderate. Provectus Pharmaceuticals currently has over 40 patients enrolled in the PV-10 compassionate use program and is in discussion with the FDA designing their Phase 3 trial. I would definately look into PV-10 as an option.  http://www.pvct.com

Dennis

Hello Lynn.

I checked with Provectus Pharmaceuticals and asked them if patients with auto immune diseases…like rheumatoid arthritus could qualify for their PV-10 Phase 3 Trial or their Compassionate Use Program and this is the answer I received.  I hope this helps. Have a great day!

Dennis, I’ve checked with Eric Wachter who runs our clinical trial programs.  He says “This is not a current exclusion criterion.”  So, the answer to your question is “yes.”

Peter R. Culpepper, CFO, COO
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931 USA
O:  866.594.5999 ext. 30
M:  865.235.5485
F:  866.998.0005
[email protected]; http://www.pvct.com
 

Hello Lynn.

I checked with Provectus Pharmaceuticals and asked them if patients with auto immune diseases…like rheumatoid arthritus could qualify for their PV-10 Phase 3 Trial or their Compassionate Use Program and this is the answer I received.  I hope this helps. Have a great day!

Dennis, I’ve checked with Eric Wachter who runs our clinical trial programs.  He says “This is not a current exclusion criterion.”  So, the answer to your question is “yes.”

Peter R. Culpepper, CFO, COO
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931 USA
O:  866.594.5999 ext. 30
M:  865.235.5485
F:  866.998.0005
[email protected]; http://www.pvct.com